Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay–Sachs disease

17 Jun 2005

Abstract excerpt

Therapy for neurodegenerative lysosomal Tay-Sachs (TS) disease requires active hexosaminidase (Hex) A production in the central nervous system and an efficient therapeutic approach that can act faster than human disease progression. We combined the efficacy of a non-replicating Herpes simplex vector encoding for the Hex A alpha-subunit (HSV-T0alphaHex) and the anatomic structure of the brain internal capsule to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular transport and secretion
Share to Lysosomal Storage Disorders Research
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15961412
DOI: 10.1093/hmg/ddi216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay–Sachs diseasePMID 15961412Read ↗

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosisSemantic proximity Read ↗

Human Recombinant Lysosomal β-Hexosaminidase A produced in P.pastoris efficiently reduced GM2 ganglioside accumulation in Tay- Sachs DiseaseSemantic proximity Read ↗

Adenoviral Gene Therapy of the Tay-Sachs Disease in Hexosaminidase A-Deficient Knock-Out MiceSemantic proximity Read ↗

Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.Semantic proximity Read ↗

Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.Semantic proximity Read ↗

Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage studySemantic proximity Read ↗

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I.Semantic proximity Read ↗

Effective gene therapy for an inherited CNS disease in a large animal modelSemantic proximity Read ↗

First-in-human AAV Gene Therapy for Tay-Sachs DiseaseSemantic proximity Read ↗

Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.Semantic proximity Read ↗

Antero‐ventral internal pallidum stimulation improves behavioral disorders in Lesch–Nyhan diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.